CHESHIRE, UK--(MARKET WIRE)--Nov 3, 2008 --

 

Protherics PLC


Total Voting Rights and Share Capital



London, UK; Brentwood, TN; 3 November 2008 - In conformity with the
Transparency Directive,  Protherics PLC ("Protherics"), the
international biopharmaceutical company focused on critical care and
cancer, notifies the market of the following:


Protherics' issued share capital consists of 350,427,481 ordinary
shares with a nominal value of 2 pence each, with voting rights.
Protherics does not hold any ordinary shares in Treasury.  Therefore,
the total number of voting rights in Protherics is 350,427,481.


The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Protherics
under the Financial Services Authority's Disclosure and Transparency
Rules.                             / Ends /




For further information please contact:


Protherics

Nick Staples, Director of Corporate Affairs    +44 (0) 7919 480510

Julie Vickers, Company Secretary               +44 (0)1928 518010


Financial Dynamics - press enquiries

London: Ben Atwell, Lara Mott                  +44 (0) 20 7831 3113

New York: John Capodanno                       +1 212 850 5600



Or visit  http://www.protherics.com

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

     Contacts:
     RNS
     Customer
     Services
     0044-207797-4400
     Email Contact
     http://www.rns.com